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Background 
Metastatic Melanoma (mMel) is considered refractory to conventional chemotherapies. 
New molecular targeted approaches, inhibiting mutated forms of the serine-threonine 
kinase B-RAF, significantly increased the response rate but patients almost invariably 
relapse and prognosis remains severe [1,2]. Open challenge is the characterization and 
targeting of cancer stem cells (CSCs), considered responsible for chemoresistance and 
disease relapse. Adoptive immunotherapy holds great promises for the treatment of mMel 
and research efforts are ongoing to explore its potential activity against melanoma CSCs 
(mCSCs). Cytokine Induced Killer (CIK) cells are a subset of ex vivo expanded T 
lymphocytes with mixed CD3+CD56+ phenotype and endowed with HLA-unrestricted tumor 
killing activity. We and others recently reported the preclinical activity of CIK cells against 
several solid tumors including mMel [3]. 
Aim of our research is to explore the preclinical activity of CIK cells against autologous 
mCSCs surviving treatments with chemo or molecular targeted therapies. 
Material and methods 
We set a preclinical autologous immunotherapy model with primary melanoma cultures 
and CIK cells generated from patients treated at our Center. To visualize mCSCs we 
transduced tumor cells with a lentiviral CSC-detector vector encoding enhanced Green 
Fluorescent Protein (eGFP) under control of the stem-gene oct4 promoter. We treated all 
mMel cultures with chemotherapy drug fotemustine (IC50 dose). Melanoma cultures 
harboring BRAF V600E mutations were also treated with BRAF inhibitor (BRAFi) 
dabrafenib (IC50 dose). We evaluated the presence of residual mCSCs among mMel cells 
surviving 72h of treatment and explored their susceptibility to immunotherapy with 
autologous CIK cells. 
Results 
We visualized mCSCs within 11 mMel cultures (3/11 BRAF V600E mutated); median value 
of eGFP+mCSCs was 15% (range 3.5-26.4%). Putative mCSCs displayed a relative 
resistance to conventional treatments. The presence of eGFP+mCSCs increased of 39% 
and 25% among melanoma cells that survived exposure to fotemustine and BRAFi 
respectively, compared to untreated controls (n=11). CIK cells effectively killed autologous 
mMel and mCSCs. Tumor specific killing, equally involving bulk mMel targets and mCSCs, 
ranged between 75% and 33% at effector target ratios of 40:1 and 1:1 respectively (n=8). 
Conclusion 
We provided first proof of concept that putative mCSCs are relatively resistant to 
conventional treatments with chemo or molecular targeted therapy and susceptible to 
immunotherapy killing by autologous CIK cells. These preclinical findings support the 
hypothesis that mCSC may be responsible for disease relapses and support designing of 
experimental immunotherapy clinical trials with CIK cells in mMel settings. 
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